Gyre Therapeutics, Inc.: financing cash flow
Financing cash flow for Gyre Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Gyre Therapeutics, Inc. financial histories
What this measure means
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
Exact concept: us-gaap:NetCashProvidedByUsedInFinancingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2009-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 24,378,000 | USD | 2026-03-13 | 10-K · 0001193125-26-106251 |
| 2024-01-01 | 2024-12-31 | 2,102,000 | USD | 2026-03-13 | 10-K · 0001193125-26-106251 |
| 2023-01-01 | 2023-12-31 | 2,500,000 | USD | 2025-03-17 | 10-K · 0000950170-25-040279 |
| 2022-01-01 | 2022-12-31 | -45,011,000 | USD | 2023-03-30 | 10-K · 0001564590-23-004830 |
| 2021-01-01 | 2021-12-31 | 49,553,000 | USD | 2023-03-30 | 10-K · 0001564590-23-004830 |
| 2020-01-01 | 2020-12-31 | 60,376,000 | USD | 2022-03-31 | 10-K · 0001564590-22-012877 |
| 2019-01-01 | 2019-12-31 | 327,000 | USD | 2021-03-04 | 10-K · 0001564590-21-010823 |
| 2018-01-01 | 2018-12-31 | 111,332,000 | USD | 2020-02-20 | 10-K · 0001564590-20-005546 |
| 2017-01-01 | 2017-12-31 | 21,082,000 | USD | 2019-03-08 | 10-K · 0001564590-19-006879 |
| 2013-01-01 | 2013-12-31 | -552,000 | USD | 2014-03-14 | 10-K · 0001193125-14-099974 |
| 2012-01-01 | 2012-12-31 | -626,000 | USD | 2014-03-14 | 10-K · 0001193125-14-099974 |
| 2011-01-01 | 2011-12-31 | 82,814,000 | USD | 2014-03-14 | 10-K · 0001193125-14-099974 |
| 2010-01-01 | 2010-12-31 | 6,446,000 | USD | 2013-03-15 | 10-K · 0001193125-13-109464 |
| 2009-01-01 | 2009-12-31 | 47,178,000 | USD | 2012-03-06 | 10-K · 0001193125-12-099259 |
Related financial histories
- Gyre Therapeutics, Inc.: total assets
- Gyre Therapeutics, Inc.: total liabilities
- Gyre Therapeutics, Inc.: stockholders equity
- Gyre Therapeutics, Inc.: cash and cash equivalents
- Gyre Therapeutics, Inc.: net income or loss
- Gyre Therapeutics, Inc.: operating cash flow
- Gyre Therapeutics, Inc.: capital expenditure payments
- Gyre Therapeutics, Inc.: revenue
- Gyre Therapeutics, Inc.: contract revenue excluding tax
- Gyre Therapeutics, Inc.: investing cash flow
- Gyre Therapeutics, Inc.: retained earnings or deficit
- Gyre Therapeutics, Inc.: basic weighted-average shares
- Gyre Therapeutics, Inc.: diluted weighted-average shares
- Gyre Therapeutics, Inc.: basic earnings per share
- Gyre Therapeutics, Inc.: diluted earnings per share
- Gyre Therapeutics, Inc.: income tax expense or benefit
- Gyre Therapeutics, Inc.: net property, plant and equipment
- Gyre Therapeutics, Inc.: share-based compensation expense
- Gyre Therapeutics, Inc.: operating income or loss
- Gyre Therapeutics, Inc.: current assets
- Gyre Therapeutics, Inc.: interest expense
- Gyre Therapeutics, Inc.: current liabilities
- Gyre Therapeutics, Inc.: current accounts payable
- Gyre Therapeutics, Inc.: net finite-lived intangible assets
- Gyre Therapeutics, Inc.: net current accounts receivable
- Gyre Therapeutics, Inc.: operating expenses
- Gyre Therapeutics, Inc.: net inventory
- Gyre Therapeutics, Inc.: gross profit
- Gyre Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Gyre Therapeutics, Inc. / CIK 0001124105
- Captured
- 2026-09-20T07:40:18.545Z
- SEC response SHA-256
76d6d577c67b9fd5657091e03be7ffe01a1cac0d3d9b5ad24843327a50d791e0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001124105.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))